Results 21 to 30 of about 4,131,175 (280)

Lorlatinib‐Containing Therapy for MYCN‐Amplified, ALK‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim   +11 more
wiley   +1 more source

Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclin‐dependent kinase 4/6 (CDK4/6) pathway aberrations, including CDK4 or CCND1 amplification, CDKN2A/B loss, retinoblastoma (RB) dysregulation, and cyclin D overexpression, are relevant for pediatric cancers. Abemaciclib, a selective CDK4/6 inhibitor with preferential CDK4 activity and central nervous system (CNS) penetration ...
Alvaro Lassaletta   +10 more
wiley   +1 more source

Therapeutic Apheresis in Nigeria: Awareness, Knowledge Gaps, and Readiness for Service Expansion Among Healthcare Professionals

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is a specialized extracorporeal blood purification modality used in the management of complex hematologic, neurologic, and autoimmune diseases. Despite established global guidelines, its utilization in Nigeria remains largely undocumented.
Chimezie G. Okwuonu   +11 more
wiley   +1 more source

Design and analysis strategies for robust microbiome ageing research

open access: yesFEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik   +5 more
wiley   +1 more source

BIN

open access: yes, 2019
NONE
NONE NONE (8158415)
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

none

open access: yes, 2000
\ue7 ...
, none
core   +1 more source

Best abstracts of the NVMO conference

open access: yesPerspectives on Medical Education, 2013
None
None
doaj   +1 more source

Prospecting the protein design landscape

open access: yesFEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona   +4 more
wiley   +1 more source

Introduction to this issue of Perspectives on Medical Education

open access: yesPerspectives on Medical Education, 2013
None
None
doaj   +1 more source

Home - About - Disclaimer - Privacy